NVCT Latest News, Press Relases and Analysis

All

Press Releases

6 hours ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

11 days ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

11 days ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

a month ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors

2 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

2 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

3 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

3 months ago - By: The Motley Fool

Nuvectis (NVCT) Q2 Loss Widens 43%

3 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

3 months ago - By: Benzinga - Mentions: PBM ALGN DYAI SNGX ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

3 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

3 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

4 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies

5 months ago - By: Benzinga - Mentions: RGC WORX PRTA STIM ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

5 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

5 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

6 months ago - By: Zacks Investment Research

Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect?

6 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

6 months ago - By: Yahoo Finance - Mentions: DERM PFE DHI CMG ...

Why Nuvectis Pharma, Inc. (NVCT) is Surging in 2025

6 months ago - By: Yahoo Finance - Mentions: DERM CMRX MNPR MASS

Why Journey Medical Corporation (DERM) is Surging in 2025

6 months ago - By: Yahoo Finance - Mentions: VZ DERM DHI CMG

Americans saved money in fintechs. When money went missing, FDIC was no where to be found

6 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

6 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

7 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting

7 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting

8 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

8 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

8 months ago - By: Market News Alerts

Market News Alert: Nuvectis Pharma’s NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation

8 months ago - By: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC

8 months ago - By: Market News Alerts